ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pilot Study on HPV and Cervical Cancer Screening in Mumbai (HPV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03229603
Recruitment Status : Not yet recruiting
First Posted : July 25, 2017
Last Update Posted : December 22, 2017
Sponsor:
Collaborator:
University of Arizona
Information provided by (Responsible Party):
Gauravi Ashish Mishra, Tata Memorial Hospital

Brief Summary:
The Study goals are to test feasibility and acceptability of point of care HPV testing with 227 women already accessing an existing cancer screening program in Mumbai, India. Describe HPV infection types in women screened. Compare if the quality of HPV clinician-collected and self-collected samples are equally efficient to detect HPV and cervical cancer precursor lesions. Compare the agreement between HPV GeneXpert and HPV HC2 test on the clinician-collected sample

Condition or disease Intervention/treatment Phase
HPV Infection Other: Cluster of 3000 women Not Applicable

Detailed Description:

In this pilot study, Investigators will assess the feasibility and acceptability of point of care HPV testing in an existing SVA program. There is no control group since neither the efficacy nor effectiveness is to be tested. In the pilot study the screen positive women will be referred to the Tata Memorial Hospital for further diagnostic work-up to restrict the programme logistics. While in the main study, Colposcopy and Cryotherapy will be conducted at the community level. The evaluation framework will be based on a robust D&I model called REAIM.

i.TMH staff will hold health camps to mobilize women to attend. Providers already trained in the TMH outreach program will identify women eligible for screening. After obtaining the consent, the medical social worker will collect baseline data and record the results of the GeneXpert HPV testing on self sample and health care provider collected sample.

Data Collection:

ii. Quantitative data: Data will be collected in-person by the Medical Social worker. De-identified data will be uploaded to Own Cloud, a file-sharing program in the University of Arizona, College of Nursing.

ii. Qualitative data: There will be a discussion on cultural appropriateness and possible adjustments to the procedures based on the healthcare providers' experiences with a small subset of the 227 women already screened. Between one to two focus groups will be conducted by the study investigators with assistance from local staff with a subset of women, separately to qualitatively assess acceptability of HPV testing using GeneXpert.

The focus group discussions with women participants will be audio-recorded and transcribed verbatim. The moderator will be guided by a semi-structured set of questions to facilitate discussion, and will specifically probe to elicit distinctive/ unusual behaviors or symptoms related to the program, screening and HPV testing.

In keeping with standards for objective evaluation, Dr. Menon or Kue will conduct a focus group discussion with Medical Social workers at the end of the study period for program evaluation (i.e., acceptability, potential changes in delivery, etc.). Discussions will be recorded by a note-taker, not previously associated with the study.

Given the small numbers, a think-aloud group, in a question and answer format with a note-taker to record the main points will be simply conducted with the providers. Both the facilitator and note-taker will not be among TMH staff as this may introduce bias to the conversation.

iii: Training of TMH staff to use GeneXpert: Personnel from the India office of Cepheid will train providers on how to use GeneXpert using standardized training protocols. The quality of the self- collected sample will be compared to the quality of the provider collected sample (by running two separate GeneXpert tests on each sample) to establish the feasibility of self-sampling.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 227 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Pilot Study on HPV and Cervical Cancer Screening in Mumbai
Estimated Study Start Date : April 2018
Estimated Primary Completion Date : April 2018
Estimated Study Completion Date : May 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer

Arm Intervention/treatment
Cluster of 3000 women
Cluster will be selected from an existing cervical, breast, and oral cancer screening program in Mumbai, India and its surrounding semi-urban and rural areas.
Other: Cluster of 3000 women
An evaluation of the feasibility, reach, adoption and implementation of a cervical cancer screening program where we diagnose HPV using the GeneXpert point of care testing kit prior to VIA and cryotherapy.




Primary Outcome Measures :
  1. The feasibility of HPV testing as a single visit approach will be summarized using the appropriate descriptive statistics. [ Time Frame: 3 months ]
    This will be predominantly for counts and percentages for categorical variables (e.g., number of women screened, number of women with incomplete self-collected specimens). In addition to the numbers of participants, the notes from the providers' debriefing regarding culturally appropriateness of HPV testing will be considered.


Secondary Outcome Measures :
  1. Overall agreement between clinician-collected versus self-collected samples will be compared using pairwise t tests [ Time Frame: 3 months ]
    For all pairwise comparisons, the agreement will be estimated with the kappa statistic and corresponding 95% confidence intervals. McNemar's test shall be used to detect significant differences in the discordant results (p<0.05), indicating systematic differences by assay or sample type in the detection of HPV.

  2. The focus group data will be analyzed using constant comparative data analysis to identify thematic components and sub-themes. [ Time Frame: 3 months ]
    The research team will conduct a content analysis taking the following approach set forth by Huberman and Miles.

  3. The HPV GeneXpert by health care provider and HPV HC2 samples by health care provider will be compared to study the agreement rates. [ Time Frame: 3 months ]
    For all pairwise comparisons, the agreement will be estimated with the kappa statistic and corresponding 95% confidence intervals. McNemar's test shall be used to detect significant differences in the discordant results (p<0.05), indicating systematic differences by assay or sample type in the detection of HPV.

  4. Documentation of six different genotypes/ genotype families of HPV from cervical tissue samples, which will inform the development of HPV vaccinations specific to the strains of HPV in India. [ Time Frame: 3 months ]
    The prevalence and distribution of HPV genotypes in Indian women with cervical cancer and the trends in HPV infections will be summarized using the appropriate descriptive statistics.

  5. Probe for perceptions about self-collection of vaginal samples to describe acceptability of this process. [ Time Frame: 3 months ]
    Mainly descriptive statistics in percentage, numbers and description

  6. Fit a predictive model of HPV infection(s). [ Time Frame: 3 months ]
    This will be predicted by sexual behavior, sociodemographic and clinical characteristics of the women screened, controlling for the two screening sites. A positive intra-class correlation (ICC) is expected among participants at the same screening site due to commonalities in selection, exposure, mutual interaction, or a combination of those factors. We will fit Linear Mixed Models (LMMs) and Generalized Linear Mixed Models (GLMMs) to account for various levels of correlation among participants (also known as a "mixed-model ANCOVA" (Brown, 2009). We will fit these models using SAS PROC MIXED and GLIMMIX, Version 9.3.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Females aged 30 to 55 years (the age when screening for HPV and cervical cancer is recommended) who participate in the TMH cancer screening outreach program.

Exclusion Criteria:

  • Women with a known diagnosis of cancer, any other terminal diagnosis, or who are pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03229603


Contacts
Contact: Gauravi A Mishra, M.D PSM +912224177000 ext 4634 gauravi2005@yahoo.co.in
Contact: Sharmila A Pimple, M.D PSM +912224177000 ext 4631 drsharmilapatil@yahoo.com

Locations
India
Tata Memorial Hospital Not yet recruiting
Mumbai, Mharashtra, India, 400012
Contact: Gauravi A Mishra, M.D PSM    +912224177000 ext 4634    gauravi2005@yahoo.co.in   
Sponsors and Collaborators
Tata Memorial Hospital
University of Arizona
Investigators
Principal Investigator: Gauravi A Mishra, M.D PSM Tata Memorial Hospital

Responsible Party: Gauravi Ashish Mishra, Professor and Physician, Tata Memorial Hospital
ClinicalTrials.gov Identifier: NCT03229603     History of Changes
Other Study ID Numbers: TMHPO1763
First Posted: July 25, 2017    Key Record Dates
Last Update Posted: December 22, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Gauravi Ashish Mishra, Tata Memorial Hospital:
HPV infection and Cervical cancer

Additional relevant MeSH terms:
Genital Diseases, Female
Uterine Cervical Neoplasms
Papillomavirus Infections
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
DNA Virus Infections
Virus Diseases
Tumor Virus Infections